Tata Elxsi500408Earnings call transcript
Q2 FY27 earnings call: revenue INR 1055.7 crores, EBITDA margin 21.9%, H2 seen better than H1
Transcript of the Q2 FY27 earnings conference call shared with the exchanges.
By ScoutQuest · · 2 min read
21.9%EBITDA margin for the quarter
EBITDA growth year-on-year19.7%
Operating revenue growth in constant currency2.3%
- Operating Revenue
- INR 1055.7 crores, up 2.3% in constant currency
- EBITDA
- INR 231.4 crores, up 19.7% year-on-year
- EBITDA Margin
- 21.9%, a 70 basis point sequential improvement
Headline numbers
- Operating revenue of INR 1055.7 crores, growing 2.3% in constant currency.
- EBITDA of INR 231.4 crores, growing 19.7% year-on-year.
- EBITDA margin of 21.9%, a 70 basis point improvement over the previous quarter.
- A wage increase was implemented across the workforce during the quarter, and margin still expanded sequentially.
Vertical-wise performance and deal wins
- Transportation grew quarter-on-quarter in constant currency, helped by new deal wins. A notable win is a strategic multi-year deal from a leading automotive OEM for a next-generation, cloud-based telematics and connected vehicle ecosystem.
- Aerospace saw continued traction, described as being on a small base. The company announced a strategic collaboration with Sarla Aviation to support development of Shunya, described as a step towards India's first indigenous electric vertical takeoff and landing (eVTOL) aircraft. It also won an engagement from a global aerospace supplier for a test rig and validation of commercial aircraft systems.
- Media and communication grew 3.4% quarter-on-quarter in constant currency, driven by sustained ramp-ups in key engagements and AI-led deal wins, including a GenAI-powered virtual assistant for a global technology leader.
- Healthcare and life sciences grew 3.5% quarter-on-quarter in constant currency. A notable win was from a global renal care leader for next-generation home dialysis systems, covering user experience, mechanical design, embedded systems and regulatory compliance.
Guidance and outlook from management
- Management said it remains positive on the second half and hopes H2 will be better than H1 in most businesses, with healthcare specifically expected to improve over H1.
- Geographies: US and India did very well, Japan was flattish, and Europe continued to be soft, with automotive revenues predominating in that region. Deal closures in Europe are described as wait and watch.
- Q3 is described as typically a short quarter with fewer working days, and the company is awaiting customer-specific direction on possible furloughs.
- On margins, part of the sequential gain came from cross-currency benefits and the rest from operating leverage as one-off items went away; the wage hike offset a large part of this. Operating leverage is expected to continue playing out.
What a retail investor can track from here
- Whether the growth seen across verticals carries into the second half, especially in media and healthcare where deal ramp-ups contributed.
- The pace of deal closures in Europe, which management flagged as the main area of softness.
- How much of the margin improvement sustains once cross-currency benefits and one-off effects are no longer present.
- The impact of fewer working days and customer-directed furloughs in the third quarter.
Also from Tata Elxsi
Tata Elxsi reported mixed quarterly numbers; JP Morgan maintained neutral and cut target price to Rs 3,200 from Rs 3,400
14 Oct 2026
Tata Elxsi posted Q2 results beating revenue and margin estimates, stock expected to rally
14 Oct 2026
Tata Elxsi reported good numbers though commentary on Europe was described as weakish; Tata Technologies due to report earnings next
14 Oct 2026
More numbers
- Operating revenueINR 1055.7 crores
- EBITDAINR 231.4 crores
- EBITDA margin for the quarter21.9%
- EBITDA margin improvement over previous quarter70 basis point
- EBITDA growth year-on-year19.7%
- Operating revenue growth in constant currency2.3%
- Media and communication vertical growth quarter-on-quarter3.4%
- Healthcare and life sciences vertical growth quarter-on-quarter3.5%
Source: BSE · 19 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.